Retraction of: Development of a novel class of glucose transporter inhibitors (Journal of Medicinal Chemistry (2012) 55: 8 (3827-3836) DOI: 10.1021/jm300015m);Development of a novel class of glucose transporter inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 8, 2012, Pages 3827-3836

  Wang, Dasheng ^a   Chu, Po Chen ^a   Yang, Chia Ning ^b   Yan, Ribai ^a   Chuang, Yu Chung ^b   Kulp, Samuel K ^a   Chen, Ching Shih ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL UNIVERSITY OF KAOHSIUNG   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 HYDROXY 3 TRIFLUOROMETHYLBENZYLIDENE) 3 [4,4,4 TRIFLUORO 2 METHYL 2 (2,2,2 TRIFLUOROETHYL)BUTYL]THIAZOLIDINE 2,4 DIONE; ANTINEOPLASTIC AGENT; CIGLITAZONE; GLUCOSE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST EPITHELIUM; DRUG STRUCTURE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; PROSTATE EPITHELIUM; STRUCTURAL HOMOLOGY;

EID: 84860274214     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.8b00708     Document Type: Erratum

References (41)

1. Warburg, O. On the origin of cancer cells Science 1956, 123, 309-314
2. Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel Cancer Cell 2008, 13, 472-482 (Pubitemid 351766797)
3. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 2009, 324, 1029-1033
4. Kim, J. W.; Dang, C. V. Cancer's molecular sweet tooth and the Warburg effect Cancer Res. 2006, 66, 8927-8930 (Pubitemid 44521105)
5. Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens Nat. Rev. Drug Discovery 2011, 10, 671-684
6. Gatenby, R. A.; Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004, 4, 891-899 (Pubitemid 39472955)
7. Kelloff, G. J.; Hoffman, J. M.; Johnson, B.; Scher, H. I.; Siegel, B. A.; Cheng, E. Y.; Cheson, B. D.; O'Shaughnessy, J.; Guyton, K. Z.; Mankoff, D. A.; Shankar, L.; Larson, S. M.; Sigman, C. C.; Schilsky, R. L.; Sullivan, D. C. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development Clin. Cancer Res. 2005, 11, 2785-2808 (Pubitemid 40525178)
8. Macheda, M. L.; Rogers, S.; Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer J. Cell. Physiol. 2005, 202, 654-662 (Pubitemid 40175840)
9. Calvo, M. B.; Figueroa, A.; Pulido, E. G.; Campelo, R. G.; Aparicio, L. A. Potential role of sugar transporters in cancer and their relationship with anticancer therapy Int. J. Endocrinol. 2010, 2010
10. Nishioka, T.; Oda, Y.; Seino, Y.; Yamamoto, T.; Inagaki, N.; Yano, H.; Imura, H.; Shigemoto, R.; Kikuchi, H. Distribution of the glucose transporters in human brain tumors Cancer Res. 1992, 52, 3972-3979
11. Brown, R. S.; Wahl, R. L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study Cancer 1993, 72, 2979-2985 (Pubitemid 23335044)
12. Younes, M.; Brown, R. W.; Mody, D. R.; Fernandez, L.; Laucirica, R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers Anticancer Res. 1995, 15, 2895-2898 (Pubitemid 26095119)
13. Rudlowski, C.; Becker, A. J.; Schroder, W.; Rath, W.; Buttner, R.; Moser, M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer Am. J. Clin. Pathol. 2003, 120, 691-698 (Pubitemid 37339675)
14. Haber, R. S.; Rathan, A.; Weiser, K. R.; Pritsker, A.; Itzkowitz, S. H.; Bodian, C.; Slater, G.; Weiss, A.; Burstein, D. E. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis Cancer 1998, 83, 34-40 (Pubitemid 28299626)
15. Nagase, Y.; Takata, K.; Moriyama, N.; Aso, Y.; Murakami, T.; Hirano, H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma J. Urol. 1995, 153, 798-801
16. Younes, M.; Brown, R. W.; Stephenson, M.; Gondo, M.; Cagle, P. T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival Cancer 1997, 80, 1046-51 (Pubitemid 27427603)
17. Cantuaria, G.; Fagotti, A.; Ferrandina, G.; Magalhaes, A.; Nadji, M.; Angioli, R.; Penalver, M.; Mancuso, S.; Scambia, G. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy Cancer 2001, 92, 1144-1150 (Pubitemid 32861663)
18. Stewart, G. D.; Gray, K.; Pennington, C. J.; Edwards, D. R.; Riddick, A. C.; Ross, J. A.; Habib, F. K. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score Oncol. Rep. 2008, 20, 1561-1567
19. Haber, R. S.; Weiser, K. R.; Pritsker, A.; Reder, I.; Burstein, D. E. GLUT1 glucose transporter expression in benign and malignant thyroid nodules Thyroid 1997, 7, 363-367
20. Baer, S. C.; Casaubon, L.; Younes, M. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia J. Am. Acad. Dermatol. 1997, 37, 575-577 (Pubitemid 27446727)
21. Schwartzenberg-Bar-Yoseph, F.; Armoni, M.; Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression Cancer Res. 2004, 64, 2627-2633 (Pubitemid 38523921)
22. Young, C. D.; Anderson, S. M. Sugar and fat-that's where it's at: metabolic changes in tumors Breast Cancer Res. 2008, 10, 202
23. Airley, R. E.; Mobasheri, A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics Chemotherapy 2007, 53, 233-256 (Pubitemid 47074647)
24. Park, J. B. Inhibition of glucose and dehydroascorbic acid uptakes by resveratrol in human transformed myelocytic cells J. Nat. Prod. 2001, 64, 381-384 (Pubitemid 32249812)
25. Harmon, A. W.; Patel, Y. M. Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation Breast Cancer Res. Treat. 2004, 85, 103-110 (Pubitemid 38987264)
26. Cao, X.; Fang, L.; Gibbs, S.; Huang, Y.; Dai, Z.; Wen, P.; Zheng, X.; Sadee, W.; Sun, D. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia Cancer Chemother. Pharmacol. 2007, 59, 495-505 (Pubitemid 46122328)
27. Wood, T. E.; Dalili, S.; Simpson, C. D.; Hurren, R.; Mao, X.; Saiz, F. S.; Gronda, M.; Eberhard, Y.; Minden, M. D.; Bilan, P. J.; Klip, A.; Batey, R. A.; Schimmer, A. D. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death Mol. Cancer Ther. 2008, 7, 3546-3555
28. Shanmugam, M.; McBrayer, S. K.; Qian, J.; Raikoff, K.; Avram, M. J.; Singhal, S.; Gandhi, V.; Schumacker, P. T.; Krett, N. L.; Rosen, S. T. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine J. Biol. Chem. 2009, 284, 26816-26830
29. Chan, D. A.; Sutphin, P. D.; Nguyen, P.; Turcotte, S.; Lai, E. W.; Banh, A.; Reynolds, G. E.; Chi, J. T.; Wu, J.; Solow-Cordero, D. E.; Bonnet, M.; Flanagan, J. U.; Bouley, D. M.; Graves, E. E.; Denny, W. A.; Hay, M. P.; Giaccia, A. J. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality Sci. Transl. Med. 2011, 3, 94ra70
30. Wei, S.; Kulp, S. K.; Chen, C. S. Energy restriction as an antitumor target of thiazolidinediones J. Biol. Chem. 2010, 285, 9780-9791
31. Wei, S.; Chuang, H. C.; Tsai, W. C.; Yang, H. C.; Ho, S. R.; Paterson, A. J.; Kulp, S. K.; Chen, C. S. Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein Mol. Pharmacol. 2009, 76, 47-57
32. Yang, J.; Wei, S.; Wang, D. S.; Wang, Y. C.; Kulp, S. K.; Chen, C. S. Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents J. Med. Chem. 2008, 51, 2100-2107 (Pubitemid 351503265)
33. Yang, C. C.; Wang, Y. C.; Wei, S.; Lin, L. F.; Chen, C. S.; Lee, C. C.; Lin, C. C. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation Cancer Res. 2007, 67, 3229-3238 (Pubitemid 46724861)
34. Muller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition Science 2007, 317, 1881-1886 (Pubitemid 47509426)
35. Hagmann, W. K. The many roles for fluorine in medicinal chemistry J. Med. Chem. 2008, 51, 4359-4369
36. Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry Chem. Soc. Rev. 2008, 37, 320-330
37. Joost, H. G.; Thorens, B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review) Mol. Membr. Biol. 2001, 18, 247-256 (Pubitemid 34052684)
38. Chen, C. H.; Huang, P. H.; Chu, P. C.; Chen, M. C.; Chou, C. C.; Wang, D.; Kulp, S. K.; Teng, C. M.; Wang, Q.; Chen, C. S. Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression J. Biol. Chem. 2011, 286, 9968-9976
39. Inoki, K.; Zhu, T.; Guan, K. L. TSC2 mediates cellular energy response to control cell growth and survival Cell 2003, 115, 577-590 (Pubitemid 37506046)
40. Salas-Burgos, A.; Iserovich, P.; Zuniga, F.; Vera, J. C.; Fischbarg, J. Predicting the three-dimensional structure of the human facilitative glucose transporter GLUT1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules Biophys. J. 2004, 87, 2990-2999 (Pubitemid 40468559)
41. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method Methods 2001, 25, 402-408 (Pubitemid 34164012)